KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Payables: 2015-2025

Historic Payables for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $11.8 million.

  • CRISPR Therapeutics AG's Payables fell 24.26% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.3 million, marking a year-over-year decrease of 38.07%. This contributed to the annual value of $14.7 million for FY2024, which is 61.44% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Payables stood at $11.8 million, which was up 20.97% from $9.8 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Payables peaked at $45.2 million during Q1 2023, and registered a low of $9.5 million during Q2 2024.
  • For the 3-year period, CRISPR Therapeutics AG's Payables averaged around $20.7 million, with its median value being $15.6 million (2024).
  • Per our database at Business Quant, CRISPR Therapeutics AG's Payables spiked by 215.87% in 2022 and then slumped by 65.74% in 2024.
  • CRISPR Therapeutics AG's Payables (Quarterly) stood at $14.8 million in 2021, then spiked by 85.12% to $27.4 million in 2022, then spiked by 39.08% to $38.1 million in 2023, then tumbled by 61.44% to $14.7 million in 2024, then declined by 24.26% to $11.8 million in 2025.
  • Its Payables stands at $11.8 million for Q3 2025, versus $9.8 million for Q2 2025 and $13.1 million for Q1 2025.